Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

MLND

NASDAQ:MLND

Millendo Therapeutics, Inc.

Last Close

1.12

28/06 04:00

Market Cap

11.15M

Beta: 0.48

Volume Today

1.91M

Avg: 140.97K

PE Ratio

−0.04

PFCF: −0.37

locale

market

industry

website

ipo date

peer of

Metrics